Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to assess the recurrence rate following the use of PARIETEX™ Composite Ventral Patch in primary ventral hernia repair by open approach with intra-peritoneal positioning.
Prospective, multicenter, multinational non-comparative study.
Primary Endpoint: Primary hernia recurrence* rate at 24 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and by ultrasonography.
Secondary Endpoints: Primary hernia recurrence* rate at 1, 6 and 12 month follow-up. The evaluation of hernia recurrence will be performed during a physical examination and confirmed by ultrasonography.
(*Recurrence is defined as a clinically manifested bulge or a protrusion exacerbated by a Valsalva maneuver.)
Safety Parameters:
Deep and superficial infection (A Surgical Site Infection (SSI) will be defined in the study according to the Centers for Disease Control and Prevention (CDC) criteria for diagnosis of SSI).
Pain / Chronic pain Other post-operative complications (complications related to visceral adhesions, Ileus, seroma, hematoma...) Analgesics consumption Risk factors (severity and treatment) Efficacy Parameters: Recurrence of primary ventral hernia Operative time Time of the mesh positioning Length of Hospital Stay Ease of use (Mesh handling and manipulability, comfort of use …) Return to daily activities/ work Patient satisfaction Patient comfort (Carolina's™ Comfort scale (CCS) - QoL questionnaire)
Visit Schedule:
Baseline visit (Preoperative) & Operative/Discharge visit
Post-Op:
Phone call Day 10
1 month 6 months 12 months 24 months
Duration: 12 months recruitment and 24 months follow-up Up to 12 sites in Europe and the United States will be included in this study
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PARIETEX™ Composite Ventral Patch | PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PARIETEX™ Composite Ventral Patch | Device | PARIETEX™ Composite Ventral Patch for ventral hernia repair |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary Hernia Recurrence Rate at 24 Month Follow-up. | The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography. | 24 month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| Recurrence Rate at 1, 6 and 12 Month Follow-up | The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit. | 1, 6 and 12 month follow-up. |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Score at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months | Pain evaluation as determined by a 10-point pain intensity numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain). Scores reported at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months | Various (Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients eligible for a primary ventral hernia repair with mesh by open approach (scheduled for non-emergent elective surgery with PCO VP) will be assessed for potential study participation (screening) and will be recorded in the patient log.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederik Berrevoet, MD | University Hospital Ghent (Belgium) | Principal Investigator |
| Lars N Jørgensen, MD | Bispebjerg Hospital, University of Copenhagen (Denmark) | Principal Investigator |
| Carl Doerhoff, MD | Surgicare of MO (United States) | Principal Investigator |
| Steven Hopson, MD | Hernia Centers of Excellence, VA (United States) | Principal Investigator |
| Eric KULLMAN, MD | Medicinskt Centrum i Linköping (Sweden) | Principal Investigator |
| Marco G MUZI, MD | Department of Surgery, University Hospital Tor Vergata, Roma (Italy) | Principal Investigator |
| Simon NIENHUIJS, MD | Catharina Ziekenhuis, EJ EINDHOVEN (The Netherlands) | Principal Investigator |
| Filip E Muysoms, MD | Algemene Heelkunde, AZ Maria Middelares Ghent (Belgium) | Principal Investigator |
| Tim Tollens, MD | Imelda Hospital, Bonheiden (Belgium) |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of South Florida | Tampa | Florida | 33606 | United States | ||
| Our Lady of the Lake Regional Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31311545 | Derived | Berrevoet F, Doerhoff C, Muysoms F, Hopson S, Muzi MG, Nienhuijs S, Kullman E, Tollens T, Schwartz M, Leblanc K, Velanovich V, Jorgensen LN. Open ventral hernia repair with a composite ventral patch - final results of a multicenter prospective study. BMC Surg. 2019 Jul 16;19(1):93. doi: 10.1186/s12893-019-0555-z. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | PARIETEX™ Composite Ventral Patch | PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning PARIETEX™ Composite Ventral Patch for ventral hernia repair |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Summary of Risk Factors at Baseline | Summary of Risk factors at Baseline. Risk factors include: Smoker, Obesity, Diabetes T1 & T2, Cancer, Cardiovascular disease, Hypertension, COPD, Chronic desease requiring analgesic or corticoid consumption | Baseline |
| Mesh Handling Ease of Use During Surgery | Ease of use (mesh handling and comfort of use). Surgeons were asked if they were satisfied or completely satisfied, unsatisfied or completely dissatisfied | Per- operative |
| Other Relevant Data: Operative Time | Operative time during surgery for all patient receiving PCO ventral patch | Per- operative |
| Other Relevant Data: Time of Mesh Positioning | The time of the mesh positioning during surgery | Per- operative |
| Principal Investigator |
| Karl Leblanc, MD | Our Lady of the Lake Regional Medical Center, LA (United States) | Principal Investigator |
| Mark Schwartz, MD | Monmouth Medical Center, NJ (United States) | Principal Investigator |
| Vic Velanovich, MD | University of South Florida (United States) | Principal Investigator |
| Baton Rouge |
| Louisiana |
| 78080 |
| United States |
| Surgicare of Missouri | Jefferson City | Missouri | 65101 | United States |
| Monmouth Medical Center | Long Branch | New Jersey | 07740 | United States |
| Hernia Centers of Excellence | Yorktown | Virginia | 23692 | United States |
| General Surgery - Imelda Hospital | Bonheiden | 2820 | Belgium |
| Department of Surgery, Algemene Heelkunde AZ Maria Middelares Ghent | Ghent | 9000 | Belgium |
| Universitair Ziekenhuis Gent | Ghent | 9000 | Belgium |
| Department of Surgery K, Bispebjerg Hospital, University of Copenhagen | Copenhagen | 2400 | Denmark |
| Dr. ERIC KULLMAN | Linköping | Östergötland County | 58224 | Sweden |
| COMPLETED |
|
| NOT COMPLETED |
|
Consented and enrolled population 126 (100.0) Completed Study 100 (79.4) Discontinued early 26 (20.6)
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PARIETEX™ Composite Ventral Patch | PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning PARIETEX™ Composite Ventral Patch for ventral hernia repair |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| |||||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Primary Hernia Recurrence Rate at 24 Month Follow-up. | The number of participants with hernia recurrence at 24 months, assessed during a physical examination and by ultrasonography. | 101 patients returned for 24 month Follow-Up Visit. | Posted | Count of Participants | Participants | 24 month follow-up |
|
|
| ||||||||||||||||||||||||||
| Secondary | Recurrence Rate at 1, 6 and 12 Month Follow-up | The number of participants with hernia recurrence at 1 month, 6 month and 12 month follow-up visit. | The number analyzed reflects the number of participants who returned for 1 month, 6 month and 12 month follow-up visits. | Posted | Count of Participants | Participants | 1, 6 and 12 month follow-up. |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Pain Score at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months | Pain evaluation as determined by a 10-point pain intensity numerical rating scale (NRS) ranging from 0 (no pain) to 10 (worst pain). Scores reported at Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months | The number analyzed includes participants who completed the NRS pain scale | Posted | Mean | Standard Deviation | units on a scale | Various (Baseline, Discharge, Day10, 1 Month, 6 Months, 12 Months & 24 Months) |
|
| ||||||||||||||||||||||||||
| Other Pre-specified | Summary of Risk Factors at Baseline | Summary of Risk factors at Baseline. Risk factors include: Smoker, Obesity, Diabetes T1 & T2, Cancer, Cardiovascular disease, Hypertension, COPD, Chronic desease requiring analgesic or corticoid consumption | Number of patients with risk factors at baseline | Posted | Number | participants | Baseline |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Mesh Handling Ease of Use During Surgery | Ease of use (mesh handling and comfort of use). Surgeons were asked if they were satisfied or completely satisfied, unsatisfied or completely dissatisfied | Overal patients treated with PCO Ventral patch | Posted | Count of Participants | Participants | Per- operative |
|
| |||||||||||||||||||||||||||
| Other Pre-specified | Other Relevant Data: Operative Time | Operative time during surgery for all patient receiving PCO ventral patch | Posted | Mean | Standard Deviation | min | Per- operative |
|
|
| ||||||||||||||||||||||||||
| Other Pre-specified | Other Relevant Data: Time of Mesh Positioning | The time of the mesh positioning during surgery | Posted | Mean | Standard Deviation | min | Per- operative |
|
|
|
24 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PARIETEX™ Composite Ventral Patch | PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning PARIETEX™ Composite Ventral Patch for ventral hernia repair | 1 | 126 | 21 | 126 | 41 | 126 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute myocardial infarction | Cardiac disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Umbilical hernia | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Cyst | General disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Multi-organ failure | General disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Cholecystitis | Hepatobiliary disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Device related infection | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Pneumonia legionella | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Ligament rupture | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Multiple fractures | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Post procedural fistula | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Postoperative ileus | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Pubis fracture | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Traumatic fracture | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Lipoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (17.0) | Non-systematic Assessment |
| |
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (17.0) | Non-systematic Assessment |
| |
| Teratoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (17.0) | Non-systematic Assessment |
| |
| Rectocele | Reproductive system and breast disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Decubitus ulcer | Skin and subcutaneous tissue disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Intermittent claudication | Vascular disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MedDRA (17.0) | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal hernia | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Umbilical hernia | Gastrointestinal disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Local swelling | General disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Postoperative wound infection | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Wound infection | Infections and infestations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Incision site haematoma | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Post procedural discomfort | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Procedural intestinal perforation | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Procedural nausea | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Seroma | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Wound secretion | Injury, poisoning and procedural complications | MedDRA (17.0) | Non-systematic Assessment |
| |
| Haemoglobin decreased | Investigations | MedDRA (17.0) | Non-systematic Assessment |
| |
| Vaginal haemorrhage | Reproductive system and breast disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Skin irritation | Skin and subcutaneous tissue disorders | MedDRA (17.0) | Non-systematic Assessment |
| |
| Hypotension | Vascular disorders | MedDRA (17.0) | Non-systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Michelle DiSalvo | Medtronic | 774 284 6089 | michelle.v.disalvo@medtronic.com |
| ID | Term |
|---|---|
| D006547 | Hernia |
| ID | Term |
|---|---|
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| United States |
|
| Denmark |
|
| Italy |
|
| Netherlands |
|
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
| Smoker |
| |||||
| Obesity (BMI>=30) |
| |||||
| Diabetes Type 1 |
| |||||
| Diabetes Type 2 |
| |||||
| Cancer |
| |||||
| Cardiovascular Disease |
| |||||
| Hypertension |
| |||||
| COPD |
| |||||
| Chronic Disease-Analgesic Consumption |
| |||||
| Chronic Disease-Corticoid consumption |
|
| Title | Denominators | Categories | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|